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At ite sitting of I1 April 1978 the European Parliament, purBuant to
RuIe 25 of the Rules of Precdure, referred the motion for a resolution
tabled by !{r Fellermaier, on behalf of the Seialist croup, on the nanufacture,
distribution and uae of pharmaceutical preparations (De. Lg/781 to the
Cqunittee on Econonic and Monetary Affaira.
On 28 April 1978 the Comnlttee on Econqnlc and Monctary Affalre appointed
llr De Keeramaeker rapporteur.
llhe corurrittee considered the draft report at its meetings of 25 and
26 September, 21 and 22 Nosember 1978, 23 and 24 .Ianuary and 27 and 28 February
1979 and approved it at the $sE of the'se -mEetinga by 16 votea with 2
abstentions.
Present: Iilr Notenboor, acting chairrnan; !,!I De Keersnaeker, rapporteur;
Mr Ansquer, Lord Ardwick, !,lr Cifarelli, Ir{r Damaeaux, lrlr DeSchampEr Mr G1inne,
!,lr Van der Gun, !{r Lange, li[r Leonardi, Mr Nornanton, It{r Preacott,
Sir Brandon Rhye Williams, !,tr Ripamonti, Ir|l Spine11l, !{r Starke and llr StettGr.
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AThe Committee on Economic and l.{onetary Affairs hereby subilite to the
European Parlialent the following motion for a resolution, together with
explanatory statement:
MOTION FOR A RESOLUTION
on the nianufacture, distribution and use of 'pharmaceutical preparatione
@,
- having regard to the motion for a resotution (Doc. LIfiil)L,
- 
having regard to the re5ort of the Committee on Economic and Monetary
Affairs (De. 654/78) ,
1. NoteE that the structure of the pharmaceutical induetry is
characterized by a subetant l concentration of supply in certain
categories of therapeuticaL products and that, whefe a structure
of this nature obtains, the poasibility of the rulee of competl-
tion being infringed, for instance in the matter of price fixing,
cannot be ruled out;
2. Stresses that such a stiudture-icalls for great vigilance on the part
of the Comnission as r€gards compliance with the rules ori competition
laid down by the EEC Treaty,
3. Notes with satisfaction the ConuniEsion's succesEful efforts to enaure
compliance with the rules on comp€tition laid down by the Treaty,
points, however, to the need for the ConmiEsion conetantly to consider
ways of detecting dietortiong of competition for example, wlth reepect to
the methode of fixing tranefer pricea even more efflciently and gulckly;
4. IE aware of the restrictions imposed by Articles 85 and 86 of the
EEC Treaty and of the interpretation o f those articles when dietortions
of competition are being dealt with;
5. Urges, as it has repeatedly done in the Past, the council to aPprove
as quickly as possible the Conunission's proposal on the control of
concentrations betrreen undertakings ;
6. Considers that in view of the lovr price elasticity, which provides
opportunities for abuse in price fixing, and in view of the heavy
burden borne by the social security systems, supervision at national
and Coruuunity level of the prices charged for phamaceutical preparations
may prove beneficial;
1 Motion for a resolution tabled by the Soclaligt Group
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7. Stresses, however, that the price control measures taken by the lrlember
States should be compatible with the Treaty and that they should not
restrict intra-Community trade;
8. Calls on the Commission to undertake a careful inveatigation into thc
Compatabllity with the Treaty of the varloug national prlce control EyBtems
for pharmaceutical prodrrte and to submlt lte fi4dings to Parliament;
reminds the Commission of its responsibility for ensuring conrpliance
with the provisions of the Treaty and, accordingty, to take immediate
action should particular national price control systems prove to be
incompatible with the Treaty;
9. Feels that in the case of the categories of therapeutical products on
which there is marked concentration, the Commission should keep a close
watch on price differences and that, in accordance with the task it, set
itself in the Fourth R€port on competition policy, it should investigate
ingtances of notable price differences and determine whether theee are
not in part due to a breach of the rules on competltion;
10. Considers that if an understanding of the price situation in the Commun-
ity is to be gained, the cooperation of the national authoritiee is
absolutely essentiall regrets, however, that more often than not, such
cooperation is inadequate;
11. Reguests the Commission to consider how consultt ions with national price
bodies might be arranged and to draw up an appropriate proposal;
12. Pointa out that while the Directives al.ready approved for the elimination
of barriers to intra-Community trade in pharmac€utical products, under
which licences for marketing are issued at national leveI, c€rtalnly
constitute an important step tohrards free trade in pharmaceutical producta,
they do not eliminate all barriers to such trade;
13. Requests the Commission, therefore, to Eubmit as quickly as posaible a
new propoeal for the, mutual recognition by the Member States of national
licences or for the introduction of a comnunity licence for the marketing
of pharmaceutical products, so that free trade in-pharmaceutical products
is fully implemented;
14. Requests the Commission to submit as aoon as possible an amended proposat
on advertieing and information in the pharmaceutical industry, in particular
with'a view to ccmbating the miguge of pharmdceutical preparations;
15. rnstructs its Preeident to fonrard this resolution and the report of its
eorunittee to the Council and CommiEsion of the European Cmnnunities and
to the governments and parliamentE of,'the tilember Statee.
-G_ p857.L89/fln.
BEXPIANATORY STATEIITENT
I. The structure of supplv
1. The pharmaceutical industry ie characterized by a large number of
producers and a large nurnber of products; a small number of producers
and productE, control most of the market. Ho\,vever, no eingle grouP or
product controls a very large share of the market. The pharamceutical
induetry cannot therefore be said to be oligopolistic, despite the
marked trend tor,rrards concentration. This assesgment has to be qualified,
since investigation of the relative competit,ive position of the various
therapeutic aroups has shovm that some of these grouPs control a sub-
stantial part of the market, one example of thir being the position of
Hoffmann-La Roche on the tranquillizer and vitamin marketE.
2. During the digcuseiong on thls matter, reference !ilas made to the
major multinational undertakings active in the pharmaceutical induatry.
A number of major multinational undertakings do lnddadl operate in thie
industry. There is, therefore, a real danger that certain multinationale
may infringe Articles 85 and 86 of the Treaty and thuE realize excesBive
profits. This problem is not, hovrever, peculiar to this sector. The
possibility of infringements of the rules on competition cannot be ruled
out in any sector with a market structure of this nature.
Initially, the committee was unable to agree on hos, the pharmaceuti-
cal industry's structure might affect comptiance with the rules on
competition laid dovrn by the Treaty, in particular the proflts realized
in this sector. In order to obtain more lnformatlon whlch mtght provide
a baeis for a conEensus, the commlttee decided to invlte on€ rcPrcgenta-
tive from the Trade Unlons involved and one from the lnduatry.
Mr LEVIINSON, Secretary-ceneral of the International Federation of Chemical,
Energy and ceneral Workers Unions, and Mr TIEFB.TBACIIER, until recently the
chairman of the International Federation of Pharmaceutical !4anufacturGrE
Associations, each made a statement to the committee on this subject on
21 and 22 November 1978.
3. IIow dict this hearing contribute to a solution of the probl€m on which
the committee had been unable to reach agreement and for which the hearing
was organized : i.e., the Level of profit realized in thig sector? A
brief Eunmary of the two etatements will help to anawer that gueation.
Mr LEVINSON began by describing the specific natur€ of the product
and then went on to the second faature which he felt waa central to the
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pharmaceutical industry, its multinational character. He gave a
detailed analysis of the problems posed by the multinationalE in general:
the new economic order, the inadequacy of supervision by national govern-
ments, the economic crisie, inflation, price fixing in terms of wage
costs and investment, the impact of technology on emplolment, the
selection of place of businees and geographical mobility, the division
between production and distributlon, the application of transfar prices
and the profits realized, the significance of the high level of deprecia-
tion entailed by rapid technological progreEE, financial finagling, etc.,
Mr LEVINSON'S Etatement gave for the most part a general picture of
multinational undertakings as such, with the occasional comment that,
since the pharmaceutical industry was largely in the hands of the multi-
nationals, it, too, must be guilty of such practices. It waE not
possible, however, on the basis of this statement, to paEE judgement on
certain practices in the pharmaceutical industry. And no clear anawer
was given to the problem on which the committee had been unable to reach
a connensus, namely whether or not the profit margin exceeded a
reasonable level. !{r LEITINSON'e anaw€r may be aummed up a. follows ?
only if we have a clear plcture of how pricec are determlncd, can !r€
assess fairly whether the profit margin is juatified or not, due regard
being had to the risks involved, research, etc., Only if we have a clear
picture of the structure of the tranEfer prices and knorr exactly what
margin is added at the various stages after produetion, can we assesE
whether or not the profit margin is justified. To this end, the pro-
visions relating to the notification and publication of the undertakings'
balance sheets as submitted to the tax authorities should be harmonized.
There is, however, no sign of this happening, and the poseibility of
evading these obligations by the utilization of tax havene makes it
impossible for thie informatlon to be obtained and, conaequently, for
the acceptabllity of the profite reallzed to be agseseed. Noncthelcsa,
Mr LEVINSON felt that prof,lts ln the pharmaceutlcal lndultry wcrc at a
very high lcve1.
In his statement, ltr TIEFBIBACHER referred to the way in which the
pharmaceutical industry was hampered by the absence of any harmonization
between the various national laws regulating this sector. Conseguently,
trade in these products between the lrlember States was seriousty impeded
and a conmon market in these products was still a long way off. lle
emphasized the need for progress to be made at an early date towards
such harmonization and hence towards the establishment of a comnon
market in these products.
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As for the industry's profits, Ur TIEFEIiIBACIIER emphasizedl that
production coats constLtuted only a small part of total coste, in which
reEearch and development, monitoring costs and eo forth were becoming
increaeingly significant. Profit could not be defined simply ae the
difference between the price and production costE. He also referred in
this context to the fact that current profit and price controls made it
difficult to realize exceEsive profits.
4. what conclusions can be drawn from these two Etatements with
reEpect to the profits realized in the pharmaceutical sector? No
proof was forthcoming that excessive profits were being made in this
sector. Mr LE\IINSON's etatement emphasized the opportunities for abuse
in price fixing, which would then be reflected in the profits realized
by an induetry dominated by the multinatlonale. Since the pharmaceutical
induetry waa characterized by auch a structur€, luch abusea could not be
ruled out. Ehere ie, hot ev€r, no concrete evldencc to prove that auch la
the case. paragraph 1 of the motion for a resolutlon therefore r€fera
to the danger inherent in such a etructur€. Thls danger ie not r€ttricted
to price fixing, but relates more generally to all practicee which restrict
competition.
Given the tlpe of structure involved in this sector, the CommisEion
ehould therefore be extremely vigilant in enforcing the rules on
competition laid down by the Treaty. In its ans\il€r to the guestione put
by your rapporteur, the Conmission summarizes the action taken against
pharmaceutical undertakingE on the basis of Articles 85 and 85. Some of
the cases cited concern abuse of a dominant position, such aa thc Hoffmann-
La Roche case, in respect of both the therapeutic vltamlns group and thc
tranguillizer group. In th€ Zoja caae Ln L972 thc Commlaaion also took
action against a multinational undertaklng, the Cotmerclal Solvente
Corporation, because this undertaking, which had a partial monopoly of
nitropropane, refused to reEume supplies of this substance to the Italian
company Zo)a.
5. Some of theEe infringenents are not, hor,'rever, entirely attributable
to the multinational nature of the undertakings concerned. If most of
the supply is controlled by a limited npmber of undertakings in a
partlcular therapeutic group, there ie'nothing to stoP these undertaklngs
concluding agr€€mentE on the diEtribution of the market, prices etc.
For such agreements to be mada it iE not necessary for the undertakings
involved to be multinational concernEi the nuraber of undertakings involved
must not be tbo-big, EuE-iE is -quI€e-possaEte Eo-f Eevera, -undertaklngs'-
wfridfr eaCh manufiEEu-r€-E[eir irocl--uCEs-in-Ja-Intla M€mb€r State to ccme-to
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an agreement. An example of this was the'quinine'case; one Dutch.
two German and three French undertakings, which were the biggest
suppriers of quinine on the community market and in certain third
countries, had reached an agreement fixing the terms on which they were
to purehaae raw materials and sell guinine on all the markets.
6. ft is clear from the Commission's list of cases in which it has
applied Artlclee 85 and 85 of the Treaty to the pharrnaceutical industry
that it is making every effort to ensure that the rules on competition
laid down by the Treaty are observed in this sector. But the Commission
should be constantty devising more efficient and more rapid ways of
detecting and dealing with possible distortions of competition and abuses
of power within the meaning of Articles 85 and 86 of the Treaty. The
CommisEion must, however, be provided with the necessary material-
resources to achieve these 
€nds.
7. Articles 85 and 85 contain certain conetriintr, however, by which
the Cornnrission is bound. These include, for example, the need to prove
that a dominant position exigte. In order to do so it hae to be shown
that no eubstitute product 
€xigts, a difficult task, given th€ 1arg6
nunber of products manufactured in this industry.
8. Further, it is axiomatic that the Commission can take action in
accordance with Article 85 and 86 only when trade between the Member
States is adversely affected and competition distorted or when there is
abuse of a dominant position on a large part of the Community market.
Other distortions of competition faII within the jurisdiction of national
authorities.
9. Finally, the Council should again be urged in this context to take
rapidactionontheCorrrmiesionpropo8a1onEgg@,whichurgently
needs to be applied to the pharmaceutical industry where m€rg€rs are
extremely common.
II. Special features of the pharmaceutical industry
IO. Given that pharmaceutical products are reguired for health care and
that their cost is largely reimbursed through social security systems,
there is very ltttle price elasticity in this sector. Competition does
not operate at the level of prices in the pharmaceutical sector. A
certain amount of control over prices may *rerefore be a good thing eo
as to ensure that this freedom to fix prices is not misused, especially
as most of the cost of pharmaceutical products is borne by social security
systems and thus constitutes a heavy burden on national budgets. This
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price controL must, however, be sufficiently flexible as the cost of
research must be met from the profits made from pharmaceutical preparatiors
which have already becone firmly established on the narket.
11. As these costs are borne by national budgets and not by the Community
budget, it is Logical that this control function should be entrusted to
the national governmenta and not to the Community. Indeed, it would be
impossible to exercise price control at Community leveI. Price differences
between the various Member States are not so much due to a distortion of
competition as to a whole series of ot,her factors, such as distribution,
the granting of pat,ents, exchange rates, rates of taxation, etc., It is
planned to harmonize a number of these factors, and indeed for some of them,
e.g. admission of a pharmaceutical preparation on to the market, harmoniza-
tion has already commenced, but such factors as social security systems
will not be harmonized. The exercise of Community price control in the
nine Member States is therefore virtually unfeasible, and any attempt to
implement it would founder in a tangle of red tape.
L2. The measures which the l,lember States take in order to enEure a
reasonable price level for pharmaceutical products must not, however,
infringe the provisions of the Treaty. In this connection the Commission
stated, in reply to Written Question No. 8O8/76 by Mr Coust6 on the freeze
in the price of pharmaceutical productsl: 'these measures must however be
kept within certain Iimits, notably as prescribed by the Articles of the
Treaty (30 et seq.). In this context, the court of Just.ice of the
European Communities has ruled2 that the institution by a Member State
of a maximum price - insofar as it applies to imported products - consti-
tutes a measure of equivalent effect to a quantitative restriction on
imports within the terms of Article 30 where it is fixed at such a low
leve1, taking into account the general situation of imported products as
compared to national ones, that prospective importers can only import and
market at a Ioss.
The extent to which national price control systems for pharmaceutical
products are comPatible with the provisions of the Treaty came up for
discussion again not long ago in connection with the publication of
Prof. E.J. Mestmicker's 'vereinbarkeit, von Preisregelungen auf dem
Arzneimittelmarkt mit dem Recht der Europiischen Wirtschaftgemeinschaft'
(Compatibility of price controls on the market in pharmaceutical Froducts
with the law of the European Economic Community). In statements made
apropos of this document, representatives of the industry comPlained that
some national price control systems for pharmaceutical products were
incompatible with the Treaty and impeded free trade in these products-
1 O,f No. C. 84, 4-4.L977, p- 15
2 ca"" 65fi5 and 
-88-gTn5 (oJ No. c 136, Li-6.1976, p. 5)
- 
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Hor,vever, the Commission was taking no action against these breaches of
the Treaty and was accepting the continued existence of these price
control systems without demur. This being the case, the Committee on
Economic and llonetary Affairs considere that the CornniEsion ehould, as
a matter of urgency, undertake a'detailed inveetigation into the com-
patibility with the Treaty of the various national price control systemg
and subsequently submit ite findings to Parliament. thould the Commission
find that certain national price control systems are in fact incompatible,
it should take immediate action to ensure that they are withdrawn as
guickly as poesible. After aII, under Article 155 of the Treaty, it is
t,he Commission's responsibility to ensure compliance with the pro-
visions of the Treaty.
13. Investigations into possible infringements of the Treaty's rulee on
competition used to brgin when evidence of violationa came to light. In
its Fourth Report on conpetition policyl the Commieaion alBo assumed for
itself the responsibility of inveettgating any wlde prlce dlaparltles and
finding out, while making allourance for any oth€r posalble clue€!, whcther
these price disparitieE wer€ not at leest partly due to non-compliance
with the rules on competition. In the Normanton r€port2, which was not,
however, adopted by Parliament, the Committee on Economic and Itlonetary
Affairs supported the Commission's initiative and urged it to amplify
its investigations and extend the number of goods in respect of which
price comparisons \dere carried out.
This raises the queation whether the markets of certain therapeutic
groups with a high degree of concentration and subgtantial price
disparitiee, the two criteria set by the Commiasion, ehould not be the
subject of an lnveatigation into the caueee of these dleparltlce.
L4. Thie preeuppoaes, however, that the Comniealon le awara of the
existence of any major price disparitieg between certain pharmaceutical
products in the various I[ember Statee. For thie purpose it needs to
have sufficient information concerning the prices of the large range of
products manufactured by the pharmaceutical industry in the various
countries.
The Commission cannot possibly obtain a complete picture of the price
situation from existing Corununity price surv€ys. The latter are merely
Cormrunity surveys of retail prices carried out annually since 1970 by the
Statistical Office of the European Communitiee with a view to comparing
purchasing po\rer paritiee in the various I'lember States. For certain
1 Do". Laan5
2 Do". L64n5
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commodities, however, these statisticE may contain intereeting data from
the point of view of competition. fhe retail pricee of pharuraceutical pre-
paratione were, hffrever, only investigated in the 1970 survey. The pricea of
aDout 20 products were investigated and pr-rbliahed; thie provoked a Btrong
protest from the Member States and from the pharmaceutical induetry. Pharma-
ceutlcal prepatationawere againcordred In the 1975 prtce survey, which
hae still not yct been publlshed. Thle curv€y cov€r€d between 15 and 20
categories of products, each of which contained various gharmaceutical pre-
parations, giving a total of 101 pharmaceutical preparatione. Ttre Statietical
Office does not intend to publish theEe pricee, but merely the wEighted average cal-
culated on the basis of these individual prices; this will then be used
to calculate purchasing Power parities. Even if these data are not
pr.rblished, they should still be made available to the Commission's
Directorate-General for Competition.
15. To obtain a picture of the price situation as regards this large
number of productg in the various Member States, the Commiasion needs
the cooperation of the national authoritles. Thle cooperation,,ll,
hovrever, rarely satisfactory. The Committee on Economic and Monetary
Affairs Etated its position on such cooperation in the Normanton r€portl,
which was not adopted by the EuroPean Parliament. It is impossible
for the Commission to detect abnormal disparities between prices in
the various lr{edber States, because of the wide range of products manufac-
tured by the pharmaceutical industry, without the cooperation of the
national authorities. The Committee on Economic and ltonetary Affairs
therefore urges that the necessary measurea be taken so that this
cooperation may be improved as quickly as poseible. The problem of
cooperation between the national authorities and the Commission has been
eimplified to a certain extent by the retting up of th€ Phtrmaceutical
Commlttee and the Conrmlttee for Proprictary M€diclnll Producte. HourevGr,
it might also be ueeful to eEtabllsh congultation between the various
national authorities reEponsible for price control and the Cormtission.
This would enable the national authorities to improve their price
control methods on the basis of experience with methode applied in the
other l,tember States. Moreover, the national market is too restricted for
a proper assessment to be made of the priceE of certain medicinal Products,
and the availability of information concerning the situation in other
l,lember States may be extremely useful. Finally, the ComnisEion might
obtain, in this context, the cooperation from the national authoritiee
necessary for its price compariEona.
1 
,o". L64n5
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16. Atthough price comparisons have on several occasions revealed
distortions of competition, it must be borne in mind that the matter
is somewhat more complex than that. As pointed out above, differences
in price are determined by so many economic and legal factors that
substantial differences are possible without a dietortion of competition
necesEarily being responsible for them. This prompts the Commiseion to
quote in its reply a passage from H. C@PER's etudy'European Pharma-
ceutical Pricee L964-L974'z 'International comparisons of prices are at
best extremely hazardous undertakings. Any results which emerge
need heavy qualification and cautious interpretation. Small changes
in methodology and in the sample size and composition can produce dramatic
changes in the results. In no country are all prices consistently
higher than in another.'
In its Sixth Report on comp€tition policy the Commission gtates :
'so far none of the studies carri€d out in various induetries where
sharply differing prices between Member States hr€re found to exiet hag
shovrn that the differences resulted from reetrictive agreem€nts or con-
certed practices within the meaning of Article 85 of the Treaty, or from
abuse of dominant positions within the meaning of Article 86'.
L7. However, despite the difficulties involved in carrying out price
comparisons, the Commission seems determined to use this method to expose
distortions of competition. In reply to guestions put by your rapporteur, the
Commission refers to an investigation that is now in progress into the causes
of the price distortion in the various l[ember States in respect of the msdi r' ,...-; r
cinal product 'allopurinol', sold under the trade mark 'ZyLoric', for which a
higher price is charged in Germany than in mogt of the other Member States.
18. As regards the application of Article 86 in the event of subatantial
price disparities, the iudgrment of the Court of Justice in Case 78-70
(Deutsche Grammaphon Gesellschaft v Metro-SB-Grossmlrkte) of 8 June 1971 con-
stitutes a crucial step fonrard: in this judgement it was aseumed that a con-
siderable price disparity, in the absence of any objective juetification, may
be regarded as important evidence of abuse of a dominant position within the
meaning of Article 86. The Commission recently referred to this judgment in
its decision against United Brandt. The disparity between the priees charged
by this undertaking for bananas in the various l,lember States amounts to ov€r
LOO%. According to the Commission, not even half of this price disparity can
be explained by differences in quality or by advertising costs. The Commis-
,'sion.sdecisionisnotbasedonadetaiIedcost-priceana1ysisbutonan
anal-ysis of the market situation, the prices charged by United Brandt, the
prices charged by competit6tc ctc. The judgrment of the Court of Justice in
this Case wilt be of crucial importance for the Commission,s future ability to
combat abuses in price fixing on the basis of Article 95.
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III. The free movement of.pharmacgutical preparations in the Cfimunity
19. In the absence of genuine price competition, efforts Ehould be made to
intensify competition between products. ifhe realizatLon of tlre conmon market
in pharrnaceutical preparatione would intanclfy conpetltion on thls mrket. To
Ehat end, the current barrlerg to trade harnpcrlng the frcc noveircnt of pharma-
ceutical preparations ehould be ellminated by the harmonlzatlon of national
legislation on pharmaceutical preparations.
The Council has so far adopted a number of Directives on the approximation
of legal and administtative prwisions relating to pharmaceutical preparations.
Directive OSr/OS/nScL z Itrie oirective makes the placing of a proprietary
medicinal product on the market of a l,tember State eubject to authorization by
the conpetent authority of that Member State. lltrig Directive has been in force
eince L.L.L967.
I'he follor.ring DirectiveE cane into force at the cnd of NovGrnbor L976.
pjJject*e-ao- 75/3LA/8 2, tltria Directive, adopted in !{ay 1975, Iayc
dorrn the rules with which particulara and documents concerning the results of
tests carried out witb proprietary raedicinal products, for whictr an application
for a narketing authorization haE been made, must comply. lEtrece particulars
are to be produced pursuant to the abovementioned Directive U,o.65/65/EEc.
Directive No. 75 q19 nC3: This Directive lays donn the gualifications
required of persons drawing up docuuente aad particulara concerning control
methods and results of testa which should be submitted to the con5etent
authorities in accordance with the abovementioned Directive. Further, thia
Directive determines the manner in which applicalione f,or marketing
authorizatione should be made and aulrrviEion exerciEed over thc application
of the legal provisions.
Ttre marketing authorization is granted at national IeveI. llhe authoriza-
tion must first be granted in the country of production, follwing which
authorization may be applied for in respect of the other Menber States.
Hor'rever, applicatione are to be subEnitted in the sane manner in the various
Itenber States, and the criteria applied in granting the authorization are
Conmunity criteria. This Corumunity system is applied at national level. In
order to facilitate the adoption of a coumon position by the Member States
regarding the granting of narketing authorizations, a Cormittee for
No. 22, 9.2.1965 , p. 369/65
No. L L47, 9.6.L975, P.l
No. L L47, 9.6.L975, p.13
I o.r2ot
3 o,r
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propriety l.tedicinal Products lras set up under Directive 75/3L9/EEg. trhis
management committee can give an opinion on applications to bring a particular
pharmaceutical product on to the nrarket wheneveraMember Strtehaedoubteabout
the innocuousness or efficacy of the product. If aeveral l,tenber Statee have
adopted conflicting decisions concerning the granting or revoking of an
authorization, one of the Mernber StateE concerned Eay refer-the Eltter to the
committee.
Finally, Directive 75/3L9/EEC makes authorization obligatory for manufacture
and imtrrcrts from third countries. Imports fron third countries and manufacture
should be supervised, but if supervision is exercised in a Mernber State over
the manufacture or importation of products frour third Gsufit.rid such supervision
need not be rep€ated if the products are imported into another Member State.
It should, however, be pointed out that Article 39 provides that this Directive
ehould not be applied to proprietary medicinal products placed on the market
by virtue of previouE provisions before 15 years have elapaed.
t
DecLFLon_75/32O/EEC'z This Council Decision set up a Pharmaceutical
Committee, intended primarily to deliver opinione to the Commission. In the
Pharmaceutical committee the perEonE responEible for national public health
policy may give opinions to the Conunission on matters in which they believe
Community harmonization to be desirable, on measurea deemed necessary by the
Commission and on neht Commj-ssion proPosals in ttris area.
20. These Directives represent significant progress to\irards greater freedom
of movement in intra{oununity trade in pharmaceutical producte and ln the
protection of the health of consuners. The planned transitional period before
the entry into force of the authorization arrangements for proprietary medicinal
products placed on the market by virtue of previous prorzisions iE, hoieever,
extremely long. The last renaining obstacle to free trade in pharmaceutical
products is the fact that the Conununity eyetem of authorization is lmplemented at
national Ievel. Standardization on a Ccmnunltybasie of the particulare tobe supplied
in order to obtain an authorization coneiderably sinplifies the application
procedure for obtaining authorization in the varioug Irtenber States. Furttrer,
the setting up of a Comrittee for Proprietary lledicinal Products and a
pharroaceutical Conmittee is an initial step todards coordination of decisions
regarding authorizations and constitutes the beginnings of cooperation between
the national authoritiee.
1 o.l oto . L L47, g.5.Lg75, p. 23
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The complete elimination of all barriers to trade can be achieved only
if there is a reciprocal recognition of marketing authorizations by the Uenber
States or if a Community authorization is introduced. In 1958 the ComnisEion
Eubrnitted a propoEal for a fhird Directive on the approximation of legal and
administrative provisions regarding proprietary medicinal productal, which
provided for the mutual recognition by the Member StateE of authorization for
the placing of proprietary medicinal products on the market. Parliament
delivered an opinion (Doc. 55/681 on this Commission proposal, but it has
never been dealt with by the Council.
In reply to the questions put to it in this connection the Commission
norv states: tlfhe reason why it has not so far been possible to introduce
free trade in this area is because these public health guarantees appear in
certain textsr dnd the national authorities wish to see hmr they will be
applied and what results will be obtained. It is therefore necesBary to
foster a degree of confidence through practical application rather than
create nerrr rules.'
Holrever, the comnittee on Economic and Monetary Affaira urges that
progrees should be nade in thie area aB rapidly as trrcssible and requests the
Comnission to submit a nerr.r proposal to the Council , taking account of
experience acguired and the new factors involved.
Iv. Information and advertisincr
In 1967 the Commission submitted a proposal for a directive on thiE
subject to the Council. This propoaal was amended in 1968. Parliament then
delivered an opinion on it. The Council, hotrever, was not able to reach
agreement on this proposal. In its answer to the questione put by your
rapporteur, the CommisEion points out that it ie currently updating the old
proposal in the light of present requirements. Parliament'B best courae of
action would be to deliver its opinion on all the problems arieing in thie
context when these amended propoeals are put forrrard. The Commiesion is
requested to subnit them as aoon as possible.
- OJ No. C 14, 24.2.1958, p. 4
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MOTION FOR A RESOIJUTION (oe. L8/781 ANN&.]t
tabred by !{r FELLERIT|ATER on beharf of the selariet Group
with requeat for debate by urgent preedure pursuant to Rule L4
of the RuLee of Preedure
on the manufacture, distribution and use of pharmaceutical
preparatione
The European Parliament,
1. Notes that the structure of the phlrmaceutical indurtry ie characterized
by increaaing concentration in the hande of a fErv large cmpaniee, eo
that thcy are making unrcasonably high profite at the expenee of
eonlumGra, gocLal eecurity organizatione and pubIiC health cervices;
Stregeca that euch a atrueture calIa for great vigilance on the part of
thc Cornnlrgion ea regarde compllance with thc rules on eompetition }aid
dorn by th€ EEC Trcrty;
Notes wlth aatlafactlon thc Commleaion'r sucecsgful cffortt to Gnsure
compllancc with thorc ruleg; pointr, hovrcvor, to thc necd for thc
Commlgglon conattntly to considcr ways of tackling rny diatortiona of
competition even morc efficiently and quickly;
ra avrare of the reatrictione imposed by Articlee g5 and 96 of the EEc
Treaty and of the interpretation of those articles when distortiona of
eompetition are being dealt with;
2.
3.
4.
7.
8.
5.
6.
UrgeB, aa it has repeetedly done in the prst, the Council
Comniaaton's proposal on the control of mergers aa quickly
to approve the
aa poasible;
Coneiderg that., in view of the lovr price elaaticityr cs a result of
whlch thc fixing of pricce ie open to abuee, and of the heavy burden
on aoelal aecurity ayatema, some auperviaion of thc pricc of madicines
at national and Communlty lcvcI nay be beneficial;
Streesea, however, that the price control measurea taken by the tilember
states shourd be compatibre with the Treaty and that they should not
reetrict intratonrmunity trade;
Feers that in the case of the categorieg of therapeutical produets on
which there is marked concentration, the Commission ehould keep a close
watch on price differences and that, in accordance with the task it set
itself in the Fourth RePort on competition policy, it should investigate
inctancee of notable price differcncee and dctermine whether these are
not due, at lcrlt in part, to a breach of the rures on conu)etition;
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9. con.ldcr. thrt tf.n und.rttrndlng of thc prlcc rltuatlon in the
Conmunlty tr to bc grlncd, tho coopcrttlon of tho netional authorities ia
lmpcretlvc; rcgrota, howcvor, that, rnora oftcn thu not, auch eooperatlon
ia inadcquatci
10. Requerta thc Cornmiasi.on to coneldcr hor cor.ultatione with nrtional priee
bodlcg mlght be arrrngcd and to drew up an appropriate propoaal;
11. Points out that whlle the dlrcctivce alrcady approved for the renoval of
obetructlonl to intra-Connnunity trade in pharmaceutical products, under
which licencea are issucd for markctlng et nationll level, certainly
constitute an lmportant step towerds frcc trade in pharrnaceutical
producta, thcy do not r6mov€ all obataclce to auch trade;
L2. Requests the commiagion, therefore, to eubmit aa quickly as poslible a new
propoeal for the mutual recognition by llember Strtes of national lieencce
or for the introduction of a Community licence for the rnarketing of
pharmaceutical producta, eo that free trade in pharnaceutical produets
is fully implemented;
13. RcgueatB the Comrniasion to aubmit as roon ae poaaible an amanded proposal
on advertizlng and information in the pharmaccutlcal industry in order
to countertct exceegive conaumption of pharrnaccutical preparations;
L4. Inrtructg lts Prealdent to forward this rololution to the Council and
CommlEeion of thc European Communitieg and to the gov€rnmente and
parllarnentc of the l{ember Statee.
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